AUS
NZ
UK
CA
USA
IND
On July 17, 2026, Timothy C. Barabe, a director at Heartflow Inc., acquired 5,000 shares of the company’s common stock at $19 per share, as disclosed in a beneficial ownership update filed with the Securities and Exchange Commission. This purchase increased Barabe’s direct beneficial ownership to 184,521 shares. Additionally, he was granted 5,000 fully exercisable stock options with a $19 strike price and an expiration date of August 7, 2035, raising his total derivative securities holdings to 18,710 options. This insider transaction offers investors valuable insight into Heartflow’s board-level confidence and equity positioning.
Key Points
- NASDAQ: HTFL
- Director Timothy C. Barabe bought 5,000 shares at $19 each on July 17, 2026
- Barabe’s direct common stock ownership now totals 184,521 shares
- Received 5,000 stock options exercisable at $19, expiring August 7, 2035, increasing total options to 18,710
Details of Timothy Barabe’s Common Stock Purchase
Heartflow Inc. director Timothy C. Barabe executed an open market purchase of 5,000 common shares on July 17, 2026, at $19 per share, amounting to a $95,000 investment. This transaction was reported via a Form 4 filing on July 20, 2026, which tracks insider beneficial ownership changes under Section 16 regulations. The shares were acquired directly in Barabe’s name without intermediaries or trusts.
Following this acquisition, Barabe’s direct beneficial ownership stands at 184,521 shares, representing a significant stake in the cardiac imaging diagnostics company. Although the filing lists the transaction code as "M," typically indicating a non-open market acquisition, the disclosure confirms this was an open market purchase. Insider purchases like this often signal confidence from company leadership regarding Heartflow’s valuation and future prospects.
Stock Option Grant and Derivative Holdings
Alongside the stock purchase, Barabe received a grant of 5,000 stock options on July 17, 2026. These options have a strike price of $19, matching the purchase price of the common shares, are fully exercisable immediately, and expire on August 7, 2035, providing a nine-year exercise window. This long-term incentive aligns Barabe’s interests with Heartflow’s sustained growth and stock appreciation.
The option grant increased Barabe’s total derivative securities holdings to 18,710 options, all held directly. This compensation approach reflects Heartflow’s strategy to retain board members and align their incentives with shareholder value creation over an extended period.
Overview of Heartflow’s Market and Business Model
Heartflow Inc. specializes in cardiac imaging and diagnostics, offering proprietary software that utilizes computational fluid dynamics to deliver personalized coronary assessments. This non-invasive technology enables clinicians to evaluate coronary artery disease without invasive catheterization, positioning Heartflow within the digital health and precision medicine sectors. Its solutions are marketed to hospitals, imaging facilities, and cardiology practices both domestically and internationally.
The company generates revenue through licensing its diagnostic platform, providing professional image analysis services, and recurring software subscription and usage fees. Heartflow addresses a growing market demand for non-invasive cardiovascular diagnostics, benefiting from broader healthcare adoption of digital technologies. Insider transactions such as Barabe’s purchase reflect board confidence in Heartflow’s strategic execution and market positioning.
Transaction Timing and Regulatory Filing
The July 17, 2026 transaction was reported within the required three-business-day window on July 20, 2026. Barabe is identified as a director and Section 16 insider, responsible for timely reporting of beneficial ownership changes. The Form 4 filing was submitted solely by Barabe, with authorization granted via power of attorney to Nga Van, a common administrative practice for insider filings.
The filing affirms the accuracy and completeness of the disclosed information, with federal law imposing penalties for intentional misstatements. Barabe holds direct beneficial ownership of both the common shares and the newly granted options, with no indirect ownership reported, consistent with typical executive director equity arrangements.
Investor Implications of Insider Ownership Activity
Director stock purchases and option grants are closely watched indicators of insider confidence. Barabe’s acquisition of 5,000 shares at $19, alongside options at the same strike price, suggests he views the current valuation favorably. His total holding of 184,521 shares underscores a meaningful commitment to Heartflow’s equity.
The concurrent option grant incentivizes long-term value creation, with a nine-year exercise period encouraging alignment with shareholder interests. While insider buying is not a guarantee of stock appreciation, it provides insight into management’s outlook. Investors should consider these insider moves alongside fundamental financial and market factors when evaluating Heartflow.
Regulatory Framework and Insider Reporting Requirements
As a publicly traded company under the Securities Exchange Act of 1934, Heartflow requires directors like Barabe to comply with Section 16 reporting obligations. The Form 4 filed on July 20, 2026, discloses changes in beneficial ownership to the SEC and the public via the EDGAR database, promoting transparency in insider trading activity.
This regulatory framework enhances market integrity by providing timely disclosure of insider transactions, enabling investors to monitor insider sentiment and ownership trends. Barabe’s filing fully complies with these requirements, offering material information on his equity holdings at Heartflow.
Considerations for Heartflow Investors
The disclosed insider transaction provides a historical snapshot of equity ownership as of July 20, 2026, without projecting future performance or insider activity. No forward-looking financial guidance or strategic updates accompanied the filing. Investors should view this insider activity as one data point among many when assessing Heartflow’s prospects.
Heartflow operates in a competitive cardiac diagnostics and digital health environment influenced by technology adoption, reimbursement policies, product innovation, and regulatory approvals. Insider purchases may indicate confidence but should be weighed alongside financial results, market conditions, and competitive dynamics. Insider buying does not guarantee positive stock performance and should not be the sole basis for investment decisions.
Summary of Common Stock and Derivative Holdings
Timothy C. Barabe holds substantial equity in Heartflow through 184,521 shares of common stock and 18,710 stock options. The recent 5,000-share purchase and 5,000-option grant on July 17, 2026, reflect ongoing accumulation and incentive alignment. The $19 strike price matches the market price at purchase, consistent with fair market valuation standards for equity compensation.
The nine-year option expiration exceeds typical durations, indicating Heartflow’s preference for extended incentive periods. Barabe’s direct ownership confers full beneficial and voting rights, underscoring his significant financial stake and alignment with shareholder interests.
